Executive Summary Information
|Mechanisms||Toxicity is initiated by oxidative damage associated both with the hydroquinone moiety and with iron-complexes of the parent compound. The major metabolic product is more toxic than the parent, but metabolism is not a requirement for toxicity. This compound intercalates with DNA and thus causes direct damage to DNA as well as to proteins. Toxicity is both acute and chronic and is life-threatening.|
|Comments||This compound was selected as an archetypical repeated dose cardiotoxin.|
|Feedback Contact||Gold Compound Working Group (GCWG)|
FDA and Label Information
The following link will display all of the currently approved FDA drug products on the market. The web page will contain a table listing all current products by their respective Tradenames and primary active ingredients. The list is navigable by simply clicking on the product of interest, which will in turn list all of the NDA's and ANDA's associated with that product. From here users can click on a specific NDA or ANDA and see documents that have been submitted for the product that the FDA has made available via their website. The types of documents include approval history, letters, reviews and labels.
FDA Approved Products
This next url will perform a search in the FDA's system for all labels for products that contain Doxorubicin as an active ingredient.
FDA Label Search
Since every unique drug product receives a separate label, we have included a link to another resource for a specific Doxorubicin product (Doxorubicin hydrochloride injection, solution by Pfizer Laboratories Div Pfizer Inc.) which displays the drug label information.
The following resource link will perform a PubMed query for the terms "doxorubicin" and "cardio toxicity".
The recommended source is Sigma Aldrich, product number 44583.
|Mol Weight||Doxorubicin hydrochloride 579.98|
|Comment||Product tested for for its suitability in fluorescence applications|
|Storage||Store at +2-8 °C|
|Stability||Light sensitive. Stable for at least 1 year after receipt when stored at room temperature. Stock solutions are stable for up to 3 months at -20<B0>C. (Enzo Lifescience product n.BML-GR319-0005)|